IgGenix
PrivateLast Round
Series B
Feb 6, 2023
Total Funding Raised
$75M
Momentum Score
25 /100
Company Overview
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform designed to accelerate clinical responses to allergies by engineering antibodies that effectively capture allergens and enhance immune modulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IgGenix Comps
Public and private peers based on sector, stage, and business model.
IgGenix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 6, 2023 | ||||
| Series A Extension | Jul 27, 2021 | ||||
| Series A | Aug 4, 2020 |
Key People
Founding team and executive leadership
IgGenix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AllerFund | Series A Extension, Series B |
| Khosla Ventures | Series B, Series A, Series A Extension |
| ShangBay Capital | Series A Extension |
| Alexandria Venture Investments | Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 10, 2025
Will present Alpha-gal Syndrome discovery at 2025 AAAAI / WAO Joint Congress.
- Feb 10, 2025
Launched a program for Alpha-gal Syndrome monoclonal antibody discovery.
IgGenix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about IgGenix's valuation, stock price, and market status.
